Ver­tex sharp­ens fo­cus on gene-edit­ing in li­cens­ing deal with Mer­ck KGaA

Two years ago Mer­ck KGaA splurged $230 mil­lion to li­cense all the rights to four on­col­o­gy pro­grams, in­clud­ing a DNA-de­pen­dent pro­tein ki­nase (DNA-PK) in­hibitor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.